Neuroendocrine tumors respond to somatostatin-guided radiotherapy

Article

CONTEXT: Indium-labeled somatostatin formed the first wave of cell-surface receptor scintigraphy in the mid-1990s. While its value was limited to diagnosing and staging neuroendocrine tumors (NET), the molecularly based agent has proved superior to CT and MR in these roles. Dr. Eric P. Krenning of Erasmus University Medical Center in the Netherlands has expanded its role by labeling somatostatin with therapeutic radionuclides, producing a peptide-receptor therapy.

RESULTS: More than 400 patients with NET-expressing somatostatin receptors have undergone radiotherapy at the Erasmus hospital since 1992. The standard protocol employs a somatostatin targeting agent and either lutetium-177 or yttrium-90 beta-particle emitters for therapy. The approach has proved increasingly effective at shrinking tumors, especially with the third-generation analog lutetium-177 DOTA-Tyr3 octreotide, according to Krenning.

Treatments involving three or four sessions over eight to nine weeks have cut the volume of tumors in more than half for 20% to 30% of patients. On average, the effect of the second-generation analog lasts for at least 36 months, helping to reduce fatigue, insomnia, and pain. More than half of the patients treated with the second-generation analog have survived at least five years.

IMPLICATIONS: Although molecular imaging is billed as the next big thing in radiology, it has had a decade-long influence on the diagnosis, staging, and treatment of neuroendocrine tumors. Data suggest that patients receiving somatostatin receptor-guided therapy have fewer symptoms and longer survival than patients treated with chemotherapy. Krenning reported his results at the Society for Molecular Imaging meeting in September.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.